Alume Delivers Positive Topline Results for Bevonescein, a Potential First-in-Class Surgical Nerve Visualization Drug
Alume Biosciences delivers positive topline results for three pivotal trials of Bevonescein, advancing toward NDA submission with US FDA in 2H 2026 SAN DIEGO, CA, UNITED STATES, February 27, 2026 /EINPresswire.com/ -- Alume Biosciences, a …